Taiwan · Delayed Price · Currency is TWD Sunny Pharmtech Statistics
Total Valuation
Sunny Pharmtech has a market cap or net worth of TWD 1.96 billion. The enterprise value is 2.40 billion.
| Market Cap | 1.96B |
| Enterprise Value | 2.40B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sunny Pharmtech has 148.84 million shares outstanding. The number of shares has increased by 0.22% in one year.
| Current Share Class | 148.84M |
| Shares Outstanding | 148.84M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 17.86% |
| Owned by Institutions (%) | 3.56% |
| Float | 105.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.77 |
| PB Ratio | 2.60 |
| P/TBV Ratio | 2.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.91, with a Debt / Equity ratio of 0.64.
| Current Ratio | 0.91 |
| Quick Ratio | 0.42 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.57 |
| Interest Coverage | -30.65 |
Financial Efficiency
Return on equity (ROE) is -33.53% and return on invested capital (ROIC) is -14.85%.
| Return on Equity (ROE) | -33.53% |
| Return on Assets (ROA) | -13.27% |
| Return on Invested Capital (ROIC) | -14.85% |
| Return on Capital Employed (ROCE) | -28.08% |
| Weighted Average Cost of Capital (WACC) | 4.99% |
| Revenue Per Employee | 1.60M |
| Profits Per Employee | -1.91M |
| Employee Count | 158 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 1.77 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.29% in the last 52 weeks. The beta is 0.28, so Sunny Pharmtech's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -12.29% |
| 50-Day Moving Average | 14.04 |
| 200-Day Moving Average | 15.05 |
| Relative Strength Index (RSI) | 41.70 |
| Average Volume (20 Days) | 440,950 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sunny Pharmtech had revenue of TWD 253.01 million and -302.05 million in losses. Loss per share was -2.03.
| Revenue | 253.01M |
| Gross Profit | 73.14M |
| Operating Income | -317.53M |
| Pretax Income | -302.05M |
| Net Income | -302.05M |
| EBITDA | -198.79M |
| EBIT | -317.53M |
| Loss Per Share | -2.03 |
Balance Sheet
The company has 47.77 million in cash and 484.37 million in debt, with a net cash position of -436.61 million or -2.93 per share.
| Cash & Cash Equivalents | 47.77M |
| Total Debt | 484.37M |
| Net Cash | -436.61M |
| Net Cash Per Share | -2.93 |
| Equity (Book Value) | 754.95M |
| Book Value Per Share | 5.07 |
| Working Capital | -24.62M |
Cash Flow
In the last 12 months, operating cash flow was -158.99 million and capital expenditures -29.33 million, giving a free cash flow of -188.32 million.
| Operating Cash Flow | -158.99M |
| Capital Expenditures | -29.33M |
| Depreciation & Amortization | 118.74M |
| Net Borrowing | 98.08M |
| Free Cash Flow | -188.32M |
| FCF Per Share | -1.27 |
Margins
Gross margin is 28.91%, with operating and profit margins of -125.50% and -119.38%.
| Gross Margin | 28.91% |
| Operating Margin | -125.50% |
| Pretax Margin | -119.38% |
| Profit Margin | -119.38% |
| EBITDA Margin | -78.57% |
| EBIT Margin | -125.50% |
| FCF Margin | n/a |
Dividends & Yields
Sunny Pharmtech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.22% |
| Shareholder Yield | -0.22% |
| Earnings Yield | -15.37% |
| FCF Yield | -9.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sunny Pharmtech has an Altman Z-Score of 0.9 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.9 |
| Piotroski F-Score | 2 |